Typicality: | 0.423 |
Saliency: | 0.405 |
as ipilimumab | 5 | other |
recently | 4 | temporal |
in december | 4 | temporal |
therapy → be approved by → the fda | 24 |
therapy → be approved by → the food and drug administration | 6 |
negative | neutral | positive |
0.061 | 0.535 | 0.404 |
Raw frequency | 30 |
Normalized frequency | 0.405 |
Modifier score | 0.500 |
Perplexity | 28.972 |